ABT•November 21, 2026 at 5:35 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Abbott's Five-Year Slide Deepens Despite Exact Sciences Bet

Read source article

What happened

Abbott has lost more than 10% year-to-date, and a $1,000 investment made five years ago is now worth less than $950, reflecting persistent investor skepticism despite the company's diversified portfolio. The $21 billion acquisition of Exact Sciences added a cancer diagnostics platform and boosted reported diagnostics sales, but it also brought significant debt and EPS dilution, and the market has not rewarded the deal. While medical devices continue to grow high-single digits, led by electrophysiology and diabetes care, nutrition remains a drag with volume declines, and the FDA warning letter on Libre manufacturing adds quality risk. Abbott's valuation at 34.5x earnings leaves little margin for error, and the stock's decline over the past year reflects a loss of confidence in the growth narrative beyond devices. The company's second-quarter results and raised guidance improved near-term sentiment, but the stock remains below its five-year high, and investors are questioning whether the Exact deal or other catalysts will finally turn the story around.

Implication

The core medtech franchises are performing well, but the stock's poor five-year total return suggests that multiple compression and acquisition integration risks are outweighing operational gains. Until Exact Sciences demonstrates meaningful earnings accretion and the FDA quality issues at Abbott Diabetes Care are resolved, the stock is unlikely to re-rate higher from its current P/E. Nutrition's ongoing volume declines add another layer of uncertainty, making it difficult to forecast a return to consistent growth across all segments. A more attractive entry point near $98 would require evidence of improving nutrition trends, sustained high-single-digit device growth, and progress on margin expansion in cancer diagnostics. For existing holders, patience is warranted, but new money should wait for a better risk-reward setup or a clear inflection in the lagging businesses.

Thesis delta

The prior thesis already reflected caution on valuation and Exact dilution, but the news that $1,000 invested five years ago is now worth less than $950 strengthens the bear case that Abbott's growth has not translated into shareholder returns. The core WAIT rating remains intact, but the attractive entry level of $98 may need to be revisited if no catalyst emerges to reverse the long-term negative total return.

Confidence

medium